In prostate cancer, UBE2M interacts with NRPL2 and stabilizes its protein, and depletion of NRPL2 or UBE2M significantly increases the niraparib sensitivity of CRPC cells and enhances niraparib-induced tumor growth inhibition [50]. Here, UBE2M is linked to prostate carcinoma.